Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $33 Price Target

DAY ONE BIOPHARMACEUTICALS, INC. +2.14%

DAY ONE BIOPHARMACEUTICALS, INC.

DAWN

15.76

+2.14%

Needham analyst Ami Fadia reiterates Day One Biopharmaceutical (NASDAQ: DAWN) with a Buy and maintains $33 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via